NASDAQ:ASRT Assertio (ASRT) Stock Price, News & Analysis $0.65 0.00 (-0.06%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.64 0.00 (-0.72%) As of 05/2/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Assertio Stock (NASDAQ:ASRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Assertio alerts:Sign Up Key Stats Today's Range$0.62▼$0.6750-Day Range$0.53▼$0.8252-Week Range$0.51▼$1.80Volume506,411 shsAverage Volume709,523 shsMarket Capitalization$62.22 millionP/E RatioN/ADividend YieldN/APrice Target$2.75Consensus RatingBuy Company OverviewAssertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Read More… Assertio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreASRT MarketRank™: Assertio scored higher than 39% of companies evaluated by MarketBeat, and ranked 615th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAssertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAssertio has only been the subject of 1 research reports in the past 90 days.Read more about Assertio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Assertio are expected to grow in the coming year, from ($0.15) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAssertio has a PEG Ratio of 3.25. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAssertio has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Assertio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.05% of the float of Assertio has been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Assertio has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.05% of the float of Assertio has been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.Change versus previous monthShort interest in Assertio has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.84 News SentimentAssertio has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Assertio this week, compared to 2 articles on an average week.Search Interest3 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Assertio is held by insiders.Percentage Held by Institutions48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Assertio's insider trading history. Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address ASRT Stock News HeadlinesAssertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025March 20, 2025 | globenewswire.comAssertio Holdings price target lowered to $3.50 from $4 at H.C. WainwrightMarch 19, 2025 | markets.businessinsider.comElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.May 3, 2025 | Brownstone Research (Ad)Assertio price target lowered to $1.75 from $2.15 at Alliance GlobalMarch 14, 2025 | markets.businessinsider.comAssertio Holdings, Inc. (NASDAQ:ASRT) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | msn.comAssertio Therapeutics (ASRT) Gets a Buy from Lake StreetMarch 13, 2025 | markets.businessinsider.comAssertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 13, 2025 | finanznachrichten.deAssertio (ASRT) Reports Q4 Loss, Tops Revenue EstimatesMarch 12, 2025 | msn.comSee More Headlines ASRT Stock Analysis - Frequently Asked Questions How have ASRT shares performed this year? Assertio's stock was trading at $0.8711 on January 1st, 2025. Since then, ASRT shares have decreased by 25.4% and is now trading at $0.6497. View the best growth stocks for 2025 here. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) issued its earnings results on Monday, November, 11th. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. The firm earned $29.20 million during the quarter, compared to analysts' expectations of $29.29 million. Assertio had a positive trailing twelve-month return on equity of 3.79% and a negative net margin of 54.46%. Read the conference call transcript. Who are Assertio's major shareholders? Assertio's top institutional investors include Palumbo Wealth Management LLC (0.18%). Insiders that own company stock include Daniel A Peisert, Heather L Mason, William Mckee, Jeff L Vacirca, Ajay Patel, Sam Schlessinger, Paul Schwichtenberg and Brendan P O'grady. View institutional ownership trends. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), Fortress Biotech (FBIO), KALA BIO (KALA), Lipocine (LPCN) and Ovid Therapeutics (OVID). Company Calendar Last Earnings11/11/2024Today5/03/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASRT CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$3.50 Low Stock Price Target$1.75 Potential Upside/Downside+323.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth3.25Net Income$-331,940,000.00 Net Margins-54.46% Pretax Margin-33.94% Return on Equity3.79% Return on Assets1.81% Debt Debt-to-Equity Ratio0.30 Current Ratio2.01 Quick Ratio1.57 Sales & Book Value Annual Sales$124.96 million Price / Sales0.50 Cash Flow$0.58 per share Price / Cash Flow1.12 Book Value$1.46 per share Price / Book0.45Miscellaneous Outstanding Shares95,773,000Free Float92,423,000Market Cap$62.22 million OptionableOptionable Beta0.56 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ASRT) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.